Recent studies also showed the clinical efficacy of neoadjuvant pyrotinib, trastuzumab, and chemotherapy in HER2‐positive breast cancer, further supporting the feasibility of dual HER2‐targeted regimen.18 This evidence concerns the gene ERBB2 and breast cancer.